β-Catenin/TCF/LEF regulate expression of the short form human Cripto-1

Biochemical and Biophysical Research Communications

Volumn 355, Issue 1, 2007, Pages 240-244

  Hamada, Shin ^a,b   Watanabe, Kazuhide ^a   Hirota, Morihisa ^b   Bianco, Caterina ^a   Strizzi, Luigi ^a   Mancino, Mario ^a   Gonzales, Monica ^a   Salomon, David S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Catenin; Cripto 1; Wnt

Indexed keywords

BETA CATENIN; CRIPTO 1 PROTEIN; EPIDERMAL GROWTH FACTOR; GROWTH FACTOR; LYMPHOID ENHANCER FACTOR 1; TERATOCARCINOMA DERIVED GROWTH FACTOR 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; COLORECTAL TUMOR; ENHANCER REGION; EXON; GENE EXPRESSION REGULATION; HEPATOMA CELL; HUMAN; HUMAN CELL; INTRON; LIVER CELL CARCINOMA; MULTIGENE FAMILY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TANDEM REPEAT; TRANSCRIPTION REGULATION; TUMOR GENE;

BETA CATENIN; BINDING SITES; CARCINOMA; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; COLONIC NEOPLASMS; ENHANCER ELEMENTS (GENETICS); EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; LYMPHOID ENHANCER-BINDING FACTOR 1; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PROTEIN ISOFORMS; RECOMBINANT PROTEINS; RNA, MESSENGER; TCF TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 33847016833     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.01.143     Document Type: Article

References (17)

1. Reissmann E., Jornvall H., Blokzijl A., Andersson O., Chang C., Minchiotti G., Persico M.G., Ibanez C.F., and Brivanlou A.H. The orphan receptor ALK7 and the Activin receptor ALK4 mediate signaling by Nodal proteins during vertebrate development. Genes. Dev. 15 (2001) 2010-2022
2. Bianco C., Adkins H.B., Wechselberger C., Seno M., Normanno N., De Luca A., Sun Y., Khan N., Kenney N., Ebert A., Williams K.P., Sanicola M., and Salomon D.S. Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial cells. Mol. Cell. Biol. 22 (2002) 2586-2597
3. Bianco C., Strizzi L., Rehman A., Normanno N., Wechselberger C., Sun Y., Khan N., Hirota M., Adkins H., Williams K., Margolis R.U., Sanicola M., and Salomon D.S. A Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. Cancer Res. 63 (2003) 1192-1197
4. Bianco C., Strizzi L., Normanno N., Khan N., and Salomon D.S. Cripto-1: an oncofetal gene with many faces. Curr. Top. Dev. Biol. 67 (2005) 85-133
5. Wechselberger C., Strizzi L., Kenney N., Hirota M., Sun Y., Ebert A., Orozco O., Bianco C., Khan N.I., Wallace-Jones B., Normanno N., Adkins H., Sanicola M., and Salomon D.S. Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma. Oncogene 24 (2005) 4094-4105
6. Sun Y., Strizzi L., Raafat A., Hirota M., Bianco C., Feigenbaum L., Kenney N., Wechselberger C., Callahan R., and Salomon D.S. Overexpression of human Cripto-1 in transgenic mice delays mammary gland development and differentiation and induces mammary tumorigenesis. Am. J. Pathol. 167 (2005) 585-597
7. Strizzi L., Bianco C., Normanno N., Seno M., Wechselberger C., Wallace-Jones B., Khan N.I., Hirota M., Sun Y., Sanicola M., and Salomon D.S. Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Cripto-1 transgenic mice. J. Cell. Physiol. 201 (2004) 266-276
8. Giles R.H., van Es J.H., and Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta. 1653 (2003) 1-24
9. Morkel M., Huelsken J., Wakamiya M., Ding J., van de Wetering M., Clevers H., Taketo M.M., Behringer R.R., Shen M.M., and Birchmeier W. Beta-catenin regulates Cripto- and Wnt3-dependent gene expression programs in mouse axis and mesoderm formation. Development 130 (2003) 6283-6294
10. Baldassarre G., Tucci M., Lembo G., Pacifico F.M., Dono R., Lago C.T., Barra A., Bianco C., Viglietto G., Salomon D., and Persico M.G. A truncated form of teratocarcinoma-derived growth factor-1 (cripto-1) mRNA expressed in human colon carcinoma cell lines and tumors. Tumour Biol. 22 (2001) 286-293
11. Bianco C., Strizzi L., Mancino M., Rehman A., Hamada S., Watanabe K., De Luca A., Jones B., Balogh G., Russo J., Mailo D., Palaia R., D'Aiuto G., Botti G., Perrone F., Salomon D.S., and Normanno N. Identification of cripto-1 as a novel serologic marker for breast and colon cancer. Clin. Cancer Res. 12 (2006) 5158-5164
12. Hentschke M., Kurth I., Borgmeyer U., and Hubner C.A. Germ cell nuclear factor is a repressor of CRIPTO-1 and CRIPTO-3. J. Biol. Chem. 281 (2006) 33497-33504
13. Song L.N., Herrell R., Byers S., Shah S., Wilson E.M., and Gelmann E.P. Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol. Cell. Biol. 23 (2003) 1674-1687
14. Huang X., and Guo B. Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells. Cancer Res. 66 (2006) 9245-9251
15. de La Coste A., Romagnolo B., Billuart P., Renard C.A., Buendia M.A., Soubrane O., Fabre M., Chelly J., Beldjord C., Kahn A., and Perret C. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl. Acad. Sci. USA 95 (1998) 8847-8851
16. Ishitani T., Ninomiya-Tsuji J., Nagai S., Nishita M., Meneghini M., Barker N., Waterman M., Bowerman B., Clevers H., Shibuya H., and Matsumoto K. The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF. Nature 399 (1999) 798-802
17. Baldassarre G., Romano A., Armenante F., Rambaldi M., Paoletti I., Sandomenico C., Pepe S., Staibano S., Salvatore G., De Rosa G., Persico M.G., and Viglietto G. Expression of teratocarcinoma-derived growth factor-1 (TDGF-1) in testis germ cell tumors and its effects on growth and differentiation of embryonal carcinoma cell line NTERA2/D1. Oncogene 15 (1997) 927-936